Investors are watching Beijing’s annual “two sessions” this week for signs that the country will address drug pricing and shore up its drug payment system, as a new form of insurance introduced in January for expensive, innovative treatments struggles to gain traction. Near-term policy impact on the sector was likely to be limited, analysts said ahead of the annual meetings of China’s top legislature and political advisory body, which begin in Beijing on Wednesday. “We are not expecting much...